Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776953 · ClinicalTrials.gov registry record · Phase 4
Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients
A Phase 4 study of Analgesia and Emergencies, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT05776953: Recruiting Phase 4 study of Analgesia and Emergencies, sponsored by Hackensack Meridian Health.
NCT05776953 is a Phase 4 study of Analgesia and Emergencies that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 86 participants, roughly in line with the 88-participant average among 19 other Analgesia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05776953, a Phase 4 study of Analgesia and Emergencies, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective interventional study examining the effect of ketorolac at doses of 15mg versus 30 mg for duration of analgesia in emergency department patients with suspected renal colic.
Primary Outcome
This study may prospectively compare the mean Numerical Rating Scale (NRS) pain score reduction of 15 mg versus 30 mg of intravenous (IV) ketorolac at 120 minutes after administration to treat renal colic in the emergency department. The scale ranges from 0 to 10 with 0 being "no pain" and 10 being "very much pain".
Conditions Studied
Interventions
- DRUG Ketorolac
Study Locations (1)
New Jersey
- Hackensack Univarsity medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2026-03-28 |
| Phase | Phase 4 |
What NCT05776953 shows while recruiting
NCT05776953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, roughly in line with the 88-participant average among 19 other Analgesia trials with a reported enrollment target.
The record links to 4 conditions, with Analgesia appearing as the primary indexed condition, and to 1 intervention - of which Ketorolac is the first listed.
NCT05776953 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05776953 about?
NCT05776953 is a clinical study titled "Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients". This is a prospective interventional study examining the effect of ketorolac at doses of 15mg versus 30 mg for duration of analgesia in emergency department patients with suspected renal colic.
What is the current status of trial NCT05776953?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2023-12-21. Estimated completion is 2026-03-28.
What conditions does trial NCT05776953 study?
This clinical trial studies the following conditions: Analgesia, Emergencies, Renal Colic, Flank Pain.
What interventions are being tested in trial NCT05776953?
The interventions under investigation include: Ketorolac (DRUG).
Who is sponsoring clinical trial NCT05776953?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05776953 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Analgesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05776953's enrollment target sits among peer trials
86 11th of 19 higher than 9 of 19 other Analgesia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Analgesia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO
RECRUITING · Phase 4
-
Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery
RECRUITING · Phase 4
-
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
RECRUITING · Phase 4
-
TAP-patients With Robotic Assisted Lap Prostatectomy
COMPLETED · Phase 4
-
Pecto-intercostal Fascial Block (PIFB) for Postop Analgesia Following Sternotomy in Cardiac Surgery Patients
COMPLETED · Phase 4
-
Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI